Evaluation of Protein Distribution Optimization With Exercise Regimen on Nutritional Status, Body Composition and Functional Status in Patients Awaiting Liver Transplantation: The POWER-LT Randomized Clinical Trial
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 90
- 试验地点
- 2
- 主要终点
- Changes in Global Leadership Initiative on Malnutrition (GLIM)-defined malnutrition
研究概览
简要总结
This study aims to evaluate the effects of a diet with even protein distribution plus exercise (Group A) versus a diet with skewed protein distribution plus exercise (Group B) versus standard dietary and physical activity advice (Group C) on nutritional status, body composition and functional status in patients awaiting liver transplantation.
详细描述
Malnutrition and sarcopenia affect many patients awaiting liver transplantation and is associated with reduced quality of life and increased mortality. According to the current European Society for Clinical Nutrition and Metabolism (ESPEN) and European Association for the Study of the Liver (EASL) guidelines, a target of 1.2-1.5 g protein per kg body weight daily is recommended for patients with decompensated liver cirrhosis. While evidence supports that even protein distribution enhances muscle protein synthesis in healthy adults, specific protein timing recommendations are lacking for patients with end-stage liver disease.
Therefore, this randomized controlled trial aims to investigate the effects of a 12-week diet with even protein distribution plus exercise (Group A) versus skewed protein distribution plus exercise (Group B) versus standard dietary and physical activity advice (Group C), primarily on nutritional status, body composition and functional status, and secondarily on anthropometric measurements, laboratory parameters, quality of life, disease severity, complications and mortality in liver transplant candidates. Moreover, late postoperative parameters, including length of hospital stay, length of intensive care unit stay, duration of mechanical ventilation, postoperative complications, hospital readmissions, reoperations and mortality will be examined for those who undergo transplantation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •End-stage liver disease, diagnosed by transient elastography (FibroScan) or imaging-based evaluation with compatible clinical picture
- •Referred for liver transplantation and evaluated to have a high likelihood of being listed, according to primary hepatologist assessment, or already listed for liver transplantation
- •No prior formal dietary advice
排除标准
- •Age < 18 years old
- •Estimated waiting time for liver transplantation < 3 months
- •Estimated life expectancy < 3 months
- •Chronic kidney disease requiring protein restriction
- •Exercise contraindicated (e.g., active or recent variceal bleeding, severe grade of hepatic encephalopathy, refractory ascites, etc.)
- •Unstable or severe psychiatric disorder
- •Pregnancy or lactation
- •Inability to provide written informed consent
研究组 & 干预措施
Diet with even protein distribution plus exercise program
干预措施: Diet with even protein distribution plus exercise program (Behavioral)
Diet with skewed protein distribution plus exercise program
干预措施: Diet with skewed protein distribution plus exercise program (Behavioral)
Standard dietary and physical activity advice
干预措施: Standard dietary and physical activity advice (Behavioral)
结局指标
主要结局
Changes in Global Leadership Initiative on Malnutrition (GLIM)-defined malnutrition
时间窗: Baseline, 12 weeks
Malnutrition will be diagnosed using the Global Leadership Initiative on Malnutrition (GLIM) criteria. Diagnosis requires at least 1 phenotypic criterion and 1 etiologic criterion. Phenotypic criteria include: a. Non-votional weight loss (%): \> 5% within past 6 months or \> 10% beyond 6 months, b. Low body mass index (BMI, kg/m\^2): \< 20 kg/m\^2 if \< 70 years or \< 22 kg/m\^2 if \> 70 years, c. Reduced muscle mass, assessed by validated body composition measuring techniques \[e.g. Dual-Energy X-ray Absorptiometry (DEXA), Bioelectrical Impedance Analysis (BIA) or Computed Tomography (CT)\]. Etiologic criteria include: a. Reduced food intake or assimillation: ≤ 50% of energy requirements \> 1 week or any reduction for \> 2 weeks or any chronic gastrointestinal condition that adversely impacts food assimilation or absorption, b. Inflammation: acute disease/injury or chronic disease-related.
Changes in Computed Tomography (CT)-derived muscle mass
时间窗: Baseline, 12 weeks
Muscle mass will be assessed using the Skeletal Muscle Index (SMI, cm\^2/m\^2). SMI will be calculated by measuring the total cross-sectional area of skeletal muscles, from a single cross-sectional Computed Tomography (CT) image at L3 vertebral level, using Hounsfield Units of -29 to +150 HU, and normalizing to height squared (m\^2).Thresholds for reduced SMI will be considered \< 50 cm\^2/m\^2 for men and \< 39 cm\^2/m\^2 for women.
Changes in handgrip strength (kg)
时间窗: Baseline, 12 weeks
Handgrip strength (kg) will be assessed using a digital handgrip dynamometer. Thresholds for reduced muscle strength will be considered \< 27 kg for men and \< 16 kg for women.
Changes in Short Physical Performance Battery (SPPB) score
时间窗: Baseline, 12 weeks
The Short Physical Performance Battery (SPPB) includes 3 components: 3-positions balance testing (sec) (0-4 points), 4-meter gait speed test (sec) (0-4 points) and 5-times chair stand test (sec) (0-4 points), with a total score of 0-12. Higher scores indicate a better physical performance: 0-3 points for worst physical performance, 4-9 points for reduced physical performance and 10-12 points for best physical performance.
Changes in Liver Frailty Index
时间窗: Baseline, 12 weeks
The Liver Frailty Index includes 3 components: handgrip strength (kg), 5-times chair stand test (sec) and 3-positions balance testing (sec). Higher scores indicate a greater degree of frailty.
Changes in European Working Group on Sarcopenia in Older People 2 (EWGSOP2)-derived sarcopenia
时间窗: Baseline, 12 weeks
Sarcopenia will be diagnosed using the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria. Diagnosis requires low muscle strength and low muscle mass. Reduced muscle strength will be diagnozed by: a. Low handgrip strength (kg): \> 27 kg for men and \> 16 kg for women or b. Low chair stand test (sec): \>15 sec for 5-times chair stand test. Reduced muscle mass will be diagnozed by: a. Low Appendicular Skeletal Muscle Mass (ASM, kg): \< 20 kg for men and \< 15 kg for women or b. Low Appendicular Skeletal Muscle Mass Index (ASMI, kg/m\^2): \<7.0 kg/m\^2 for men and \< 5.5 kg/m\^2 for women.
次要结局
- Mortality(From baseline to 12 weeks)
- Nutritional Risk Screening-2002 (NRS-2002)-derived nutritional risk(Baseline)
- Food Frequency Questionnaire (FFQ)-derived dietary habits(Baseline)
- Malnutrition Screening Tool (MST)-derived nutritional risk(Baseline)
- Malnutrition Universal Screening Tool (MUST)-derived nutritional risk(Baseline)
- Short Nutritional Assessment Questionnaire (SNAQ)-derived nutritional risk(Baseline)
- Mini Nutritional Assessment-Short Form (MNA-SF)-derived nutritional status(Baseline)
- Nutritional Risk Index (NRI)-derived nutritional risk(Baseline)
- Prognostic Nutritional Index (PNI)-derived nutritional status(Baseline)
- Controlling Nutritional Status (CONUT)-derived nutritional status(Baseline)
- Liver Disease Undernutrition Screening Tool (LDUST)-derived nutritional risk(Baseline)
- Royal Free Hospital-Nutritional Prioritizing Tool (RHT-NPT)-derived nutritional status(Baseline)
- Dual-Energy X-ray Absorptiometry (DEXA)-derived muscle mass(Baseline)
- International Physical Activity Questionnaire (IPAQ)-derived physical activity levels(Baseline)
- Changes in Bioelectrical Impedance Analysis (BIA)-derived muscle mass(Baseline, 12 weeks)
- Changes in body weight (kg)(Baseline, 12 weeks)
- Changes in Body Mass Index (BMI, kg/m^2)(Baseline, 12 weeks)
- Changes in Mid-Arm Muscle Circumference (MAMC, cm)(Baseline, 12 weeks)
- Changes in Bristol Stool Chart(Baseline, 12 weeks)
- Changes in Chronic Liver Disease Questionnaire (CLDQ)(Baseline, 12 weeks)
- Changes in aspartate aminotransferase (AST, U/L)(Baseline, 12 weeks)
- Changes in alanine aminotransferase (ALT, U/L)(Baseline, 12 weeks)
- Changes in alkaline phosphatase (ALP, U/L)(Baseline, 12 weeks)
- Changes in gamma-glutamyltransferase (GGT, U/L)(Baseline, 12 weeks)
- Changes in total bilirubin (mg/dL)(Baseline, 12 weeks)
- Changes in direct bilirubin (mg/dL)(Baseline, 12 weeks)
- Changes in International Normalized Ratio (INR)(Baseline, 12 weeks)
- Changes in MELD-Na score(Baseline, 12 weeks)
- Changes in Child-Pugh score(Baseline, 12 weeks)
- Changes in presence of oedema and/or ascites(Baseline, 12 weeks)
- Changes in presence of jaundice(Baseline, 12 weeks)
- Changes in presence of variceal bleeding(Baseline, 12 weeks)
- Changes in presence of infections(Baseline, 12 weeks)
- Changes in presence of hepatic encephalopathy(Baseline, 12 weeks)
研究者
Kalliopi Anna Poulia
Assistant Professor
Agricultural University of Athens
